Image may be NSFW.
Clik here to view.
Clik here to view.
Ocular Therapeutix posts positive Phase 3a OTX-DP data
Ocular Therapeutix (NASDAQ:OCUL) has announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (sustained...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Ocular Therapeutix eyeing sustained drug delivery
Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic...
View Article
More Pages to Explore .....
